Par Can't Shake Antitrust Suit Over Vasopressin Access
A New Jersey federal court on Friday refused to throw out Fresenius' antitrust suit accusing Par Pharmaceutical Cos. of abusing its monopoly on an antidiuretic drug by raising prices and blocking...To view the full article, register now.
Already a subscriber? Click here to view full article